Blockade of NF- κ B Activation and Donation of Nitric Oxide: New Treatment Options in Inflammatory Bowel Disease?

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 236, 2002, Pages 37-41

  Dijkstra, G ^a   Moshage, H ^a   Jansen, P L M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Inducible Nitric Oxide Synthase; Inflammatory Bowel Disease; Nf KAPPAB; Nitric; Oxide

Indexed keywords

CORTICOSTEROID; CYTOKINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 6; MESALAZINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEASOME INHIBITOR; SALAZOSULFAPYRIDINE; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE DONOR; NOS2A PROTEIN, HUMAN;

ANTIMICROBIAL ACTIVITY; APOPTOSIS; BACTERIUM; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPLASM; ENTERITIS; ENZYME INDUCTION; EPITHELIUM CELL; EXPRESSION VECTOR; FEEDBACK SYSTEM; GENE CONTROL; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTESTINE; MACROPHAGE; MEDICAL LITERATURE; MUCOSA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE; VIRUS; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY; REVIEW;

HUMANS; INFLAMMATORY BOWEL DISEASES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 0035981659     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/003655202320621436     Document Type: Article

References (59)

1. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92 Suppl:5 S–11S.
2. Jobin C, Sartor RB. The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451 – 62.
3. Neurath MF, Becker C, Barbulescu K. Role of NF-kappa B in immune and inflammatory responses in the gut. Gut 1998; 43: 856 – 60.
4. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705 – 16.
5. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649 – 83.
6. Jobin C, Sartor RB. NF-kappa B signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflamm Bowel Dis 2000; 6: 206 – 13.
7. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998; 42: 477 – 84.
8. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterolog y 1998; 115: 357 – 69.
9. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77 – 80.
10. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, et al. Inhibition of interleukin-1-stimulate d NF-kappa B RelA/p65 phosphorylatio n by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274: 26448 – 53.
11. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappa B activity by sulfasalazine is mediated by direct inhibition of Ikappa B kinases alpha and beta. Gastroenterology 2000; 119: 1209 – 18.
12. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS, Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283 – 6.
13. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286 – 90.
14. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS, Jr. Interleukin-1 0 signaling blocks inhibitor of kappa B kinase activity and nuclear factor kappa B DNA binding. J Biol Chem 1999; 274: 31868 – 74.
15. Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappa B. J Immunol 1997; 159: 5661 – 70.
16. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioat e oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998 – 1004.
17. Conner EM, Brand S, Davis JM, Laroux FS, Palombella VJ, Fuseler JW, et al. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997; 282: 1615 – 22.
18. Jobin C, Hellerbrand C, Licato LL, Brenner DA, Sartor RB. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 1998; 42: 779 – 87.
19. Jobin C, Morteau O, Han DS, Balfour SR. Specific NF-kappa B blockade selectively inhibits tumour necrosis factor-alpha – induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology 1998; 95: 537 – 43.
20. Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappa B super-repressor in human intestinal epithelial cells. J Immunol 1998; 160: 410 – 8.
21. Mercurio F, Manning AM. NF-kappa B as a primary regulator of the stress response. Oncogene 1999; 18: 6163 – 71.
22. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995; 376: 167 – 70.
23. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135 – 42.
24. Jobin C, Haskill S, Mayer L, Panja A, Sartor RB. Evidence for altered regulation of I kappa B alpha degradation in human colonic epithelial cells. J Immunol 1997; 158: 226 – 34.
25. Naumann M. Nuclear factor-kappa B activation and innate immune response in microbial pathogen infection. Biochem Pharmacol 2000; 60: 1109 – 114.
26. Ruckdeschel K, Harb S, Roggenkamp A, Hornef M, Zumbihl R, Kohler S, et al. Yersinia enterocolitica impairs activation of transcription factor NF-kappa B: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor alpha production. J Exp Med 1998; 187: 1069 – 79.
27. Maehara K, Hasegawa T, Isobe KI. A NF-kappa B p65 subunit is indispensable for activating manganese superoxide: dismutase gene transcription mediated by tumor necrosis factor-alpha. J Cell Biochem 2000; 77: 474 – 86.
28. Schoonbroodt S, Piette J. Oxidative stress interference with the nuclear factor-kappa B activation pathways. Biochem Pharmacol 2000; 60: 1075 – 83.
29. Morel Y, Barouki R. Repression of gene expression by oxidative stress. Biochem J 1999; 342 Pt 3: 481 – 96.
30. Aggarwal BB. Apoptosis and nuclear factor-kappa B: a tale of association and dissociation. Biochem Pharmacol 2000; 60: 1033 – 9.
31. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappa B. J Clin Invest 2001; 107: 241 – 6.
32. Soler AP, Marano CW, Bryans M, Miller RD, Garulacan LA, Mauldin SK, et al. Activation of NF-kappa B is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosis. Eur J Cell Biol 1999; 78: 56 – 66.
33. Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996; 111: 871 – 85.
34. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998; 42: 180 – 7.
35. Iwashita E, Miyahara T, Hino K, Tokunaga T, Wakisaka H, Sawazaki Y. High nitric oxide synthase activity in endothelial cells in ulcerative colitis. J Gastroenterol 1995; 30: 551 – 4.
36. Dijkstra G, Moshage H, van Dullemen HM, Jager-Krikken A, Tiebosch AT, Kleibeuker JH, et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 1998; 186: 416 – 21.
37. Kolios G, Rooney N, Murphy CT, Robertson DF, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. Gut 1998; 43: 56 – 63.
38. Witthoft T, Eckmann L, Kim JM, Kagnoff MF. Enteroinvasive bacteria directly activate expression of iNOS and NO production in human colon epithelial cells. Am J Physiol Gastrointest Liver Physiol 1998; 38: G564 – 71.
39. McCafferty DM. Peroxynitrite and inflammatory bowel disease. Gut 2000; 46: 436 – 9.
40. Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 1995; 268: G673 – 84.
41. Rachmilewitz D, Karmeli F, Okon E, Bursztyn M. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut 1995; 37: 247 – 55.
42. Ribbons KA, Currie MG, Connor JR, Manning PT, Allen PC, Didier P, et al. The effect of inhibitors of inducible nitric oxide synthase on chronic colitis in the rhesus monkey. J Pharmacol Exp Ther 1997; 280: 1008 – 15.
43. Conner EM, Chen Y, Gronberg A. Effect of nitric oxide synthase (NOS) inhibition on dextran sulfate sodium (DSS)-induced colitis in rats and mice. Gastroenterology 1995; 108: A801.
44. Pfeiffer CJ, Qiu BS. Effects of chronic nitric oxide synthase inhibition on TNB-induced colitis in rats. J Pharm Pharmacol 1995; 47: 827 – 32.
45. McCafferty DM, Mudgett JS, Swain MG, Kubes P. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 1997; 112: 1022 – 7.
46. Zingarelli B, Szabo C, Salzman AL. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 1999; 45: 199 – 209.
47. McCafferty DM, Miampamba M, Sihota E, Sharkey KA, Kubes P. Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut 1999; 45: 864 – 73.
48. Qiu BS, Mashimo H, Vallance BA, Blennerhassett PA, Collins SM. Susceptibility of mice with specific NOS gene deletions to experimental colitis. Gastroenterology 1998; 114: A1065.
49. Hokari R, Kato S, Matsuzaki K, Iwai A, Kawaguchi A, Nagao S, et al. Reduced sensitivity of inducible nitric oxide synthase deficient mice to chronic colitis. Gastroenterology 2001; 120: A666.
50. Beck PL, Xavier R, Ezedi I, Mizoguchi E, Mashimo H, Bhan A, et al. Paradoxical roles of different nitric oxide synthase isoforms in colonic injury. Gastroenterology 1999; 116: A798.
51. McCafferty DM, Sihota E, Muscara M, Wallace JL, Sharkey KA, Kubes P. Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol 2000; 279: 1: G90 – 9.
52. Lundberg JO, Herulf M, Olesen M, Bohr J, Tysk C, Wiklund NP, et al. Increased nitric oxide production in collagenous and lymphocytic colitis. Eur J Clin Invest 1997; 27: 869 – 71.
53. Wallace JL, Vergnolle N, Muscara MN, Asfaha S, Chapman K, McKnight W, et al. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 1999; 117: 557 – 66.
54. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide- releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524 – 30.
55. Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B, et al. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology 1999; 116: 1089 – 106.
56. Fang FC. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997; 99: 2818 – 25.
57. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta- converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 1997; 185: 601 – 7.
58. Matthews JR, Botting CH, Panico M, Morris HR, Hay RT. Inhibition of NF-kappa B DNA binding by nitric oxide. Nucleic Acids Res 1996; 24: 2236 – 42.
59. Katsuyama K, Shichiri M, Marumo F, Hirata Y. NO inhibits cytokine-induced iNOS expression and NF-kappa B activation by interferin g with phosphorylatio n and degradatio n of Ikappa B – alpha. Arterioscler Thromb Vasc Biol 1998; 18: 1796 – 802.